Vaccine adherence in adolescents

Clinical Pediatrics

Volumn 48, Issue 8, 2009, Pages 801-811

  Lehmann, Corinne ^a   Benson, Paul A S ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Adolescents; Immunization; Public health; Vaccine adherence; Vaccine coverage

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; WART VIRUS VACCINE;

ADOLESCENCE; ARTICLE; CHICKENPOX; CHILDHOOD; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DIPHTHERIA; DRUG INDUCED HEADACHE; FATIGUE; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNIZATION; INFLUENZA; INJECTION SITE PAIN; MEASLES; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; MUMPS; PATIENT COMPLIANCE; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PREVENTIVE MEDICINE; RUBELLA; TETANUS; VACCINATION;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; GUIDELINE ADHERENCE; HEALTH SERVICES ACCESSIBILITY; HUMANS; PRACTICE GUIDELINES AS TOPIC; VACCINATION; VACCINES;

EID: 70349331073     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922809336360     Document Type: Article

References (90)

1. Middleton K., Hing E., Xu J. National Hospital Ambulatory Medical Care Survey: 2005 outpatient department summary. Adv Data. 2007: 1-34.
2. Bloom B., Cohen RA Summary health statistics for US children: National Health Interview Survey, 2006. Vital Health Stat 10. 2007: 1-79.
3. CDC. National Vaccination Coverage Among Adolescents Aged 13-17 Years-United States, 2006. MMWR. 2007 ;56: 885-888.
4. Oster NV, McPhillips-Tangum CA, Averhoff F., Howell K. Barriers to adolescent immunization: a survey of family physicians and pediatricians. J Am Board Fam Pract. 2005 ; 18: 13-19.
5. Little J. 35 million teens missing recommended vaccines. AAP News. 2000 ; 17: 81.
6. Centers for Disease Control and Prevention (CDC). Immunization of Adolescents Recommendations of the AdvisoryCommittee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR Recomm Rep. 1996 ; 45 (RR-13). 1-16.
7. Centers for Disease Control and Prevention (CDC). Recommended Immunization Schedules for Persons Aged 0 Through 18 Years-United States, 2009. MMWR. 2009 ; 57: Q1 - Q4.
8. Centers for Disease Control and Prevention (CDC). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006 ; 55 (RR-3). 1-34.
9. Centers for Disease Control and Prevention (CDC). Prevention and Control of Meningococcal Disease MMWR Recomm Rep. 2005 ; 54 (RR07). 1-21.
10. National Foundation for Infectious Diseases. The changing epidemiology of meningococcal disease among U.S. children, adolescents and young adults: National Foundation for Infectious Diseases; 2004: 1-15.
11. Centers for Disease Control and Prevention (CDC). Active bacterial core surveillance reports: Neisseria meningitidis. 1997-2002 ; Available at: http://www.cdc.gov/ncidod/dbmd/abcs/survreports.htm. Accessed February 17, 2009.
12. Centers for Disease Control and Prevention (CDC). Meningococcal Disease: Technical and Clinical Information. Available at: http://www.cdc.gov/meningitis/ tech-clinical.htm. Accessed February 17, 2009.
13. Centers for Disease Control and Prevention (CDC). Notice to Readers: Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine. MMWR. 2007 ; 56: 794-795.
14. Fishbein DB, Broder KR, Markowitz L., Messonnier N. New, and some not-so-new, vaccines for adolescents and diseases they prevent. Pediatrics. Jan 2008 ; 121 (Suppl 1): S5-14.
15. Centers for Disease Control and Prevention (CDC). Pertussis-United States, 2001-2003. MMWR. 2005 ; 54: 1283-1286.
16. Centers for Disease Control and Prevention (CDC). Pertussis surveillance report. MMWR. 2005 ; 54: 770.
17. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed). 1988 ; 296: 612-614.
18. Lambert HJ Epidemiology of a Small Pertussis Outbreak in Kent County, Michigan. Public Health Rep. 1965 ; 80: 365-369.
19. Olin P., Gustafsson L., Barreto L., et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine. 2003 ; 21: 2015-2021.
20. Salmaso S., Mastrantonio P., Tozzi AE, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001 ; 108: E81.
21. Wendelboe AM, Van Rie A., Salmaso S., Englund JA Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005 ; 24 (5 Suppl). S58-61.
22. Liese J., Stojanov S., Peters A. Duration of efficacy after primary immunization with biken acellular pertussis vaccine. Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL ; 2003.
23. Centers for Disease Control and Prevention (CDC). Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. 10 th ed. 2 nd printing, Washington DC: Public Health Foundation ; 2008.
24. Centers for Disease Control and Prevention (CDC). Use of mass Tdap vaccination to control an outbreak of pertussis in a high school-Cook County, Illinois, September 2006-January 2007. MMWR. 2008 ; 57: 796-799.
25. GlaxoSmithKline. Boostrix® prescribing information. Available at: http://us.gsk.com/products/assets/us-boostrix.pdf. 2009. Accessed February 25, 2009.
26. Sanofi Pasteur, Inc. Adacel® prescribing information. Available at: http://www.vaccineshoppe.com/image.cfm?image-type=product-pdf&pi=400-10. 2009. Accessed February 25, 2009.
27. Halperin S., Sweet L., Baxendale D., et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine ? Pediatr Infect Dis J. 2006 ; 25: 195-200.
28. Dunne EF, Unger ER, Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA. 2007 ; 297: 813-819.
29. Centers for Disease Control and Prevention (CDC). Genital HPV infection-CDC fact sheet. Available at: http://www.cdc.gov/STD/HPV/STDFact-HPV. htm. Accessed August 18, 2008.
30. Chiao EY, Giordano TP, Palefsky JM, Tyring S., El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006 ; 43: 223-233.
31. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 ; 189: 12-19.
32. Bosch FX, Lorincz A., Munoz N., Meijer CJ, Shah KV The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002 ; 55: 244-265. (Pubitemid 34293391)
33. Moscicki AB, Hills N., Shiboski S., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001 ; 285: 2995-3002.
34. Boardman LA, Stanko C., Weitzen S., Sung CJ Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents. Obstet Gynecol. 2005 ; 105: 741-746.
35. Brown DR, Shew ML, Qadadri B., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005 ; 191: 182-192.
36. Ho GY, Bierman R., Beardsley L., Chang CJ, Burk RD Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 ; 338: 423-428.
37. Koshiol J., Lindsay L., Pimenta JM, Poole C., Jenkins D., Smith JS Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008 ; 168: 123-137.
38. Schlecht NF, Kulaga S., Robitaille J., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001 ; 286: 3106-3114.
39. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society ; 2008.
40. Smith JS, Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer. 2007 ; 121: 621-632.
41. Centers for Disease Control and Prevention (CDC). Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 ; 56 (RR02). 1-24.
42. Saslow D., Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007 ; 57: 7-28.
43. Vandepapeliere P., Barrasso R., Meijer CJ, et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis. 2005 ; 192: 2099-2107.
44. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006 ; 367: 1247-1255.
45. GlaxoSmithKline. CERVARIX® Product Information Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted). Australia Pty Ltd ; 2007.
46. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 ; 356: 1915-1927.
47. Paavonen J., Jenkins D., Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007 ; 369: 2161-2170.
48. Initiative for Vaccine Research, Department of Immunizaiton, Vaccines, and Biologicals for the World Health Organization. Human papillomavirus and HPV vaccines; technical information for policy-makers and health professionals; 2007.
49. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006 ; 24: 5571-5583.
50. Brown DR, Kjaer SK, Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naïve women aged 16-26 years. J Infect Dis. 2009 ; 199: 926-935.
51. Wheeler CM, Kjaer SK, Sigurdsson K., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 209 ; 199-936 - 944.
52. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008 ; 110 (3, Suppl 1). S18-25.
53. Zhou F., Santoli J., Messonnier ML, et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med. 2005 ; 159: 1136-1144.
54. Caro JJ, Moller J., Getsios D., et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health. 2007 ; 7: 130.
55. Lee GM, Lebaron C., Murphy TV, Lett S., Schauer S., Lieu TA Pertussis in adolescents and adults: should we vaccinate ? Pediatrics. 2005 ; 115: 1675-1684.
56. Caro JJ, Getsios D., El-Hadi W., Payne K., O'Brien JA Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J. 2005 ; 24 (Suppl 5). S75-82.
57. Barnabas RV, Laukkanen P., Koskela P., Kontula O., Lehtinen M., Garnett GP Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006 ; 3: e138.
58. Taira AV, Neukermans CP, Sanders GD Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. Nov 2004 ; 10: 1915-1923.
59. Reisinger KS, Block SL, Lazcano-Ponce E., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007 ; 26: 201-209.
60. Block SL, Nolan T., Sattler C., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 ; 118: 2135-2145.
61. Petaja T., Keranen H., Karppa T., et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009 ; 44: 33-40.
62. Insinga RP, Dasbach EJ, Elbasha EH Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005 ; 23: 1107-1122.
63. Shepard CW, Ortega-Sanchez IR, Scott RD, 2nd, Rosenstein NE Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States Pediatrics. 2005 ; 115: 1220-1232.
64. Slonim AB, Roberto AJ, Downing CR, et al. Adolescents' knowledge, beliefs, and behaviors regarding hepatitis B: Insights and implications for programs targeting vaccine-preventable diseases. J Adolesc Health. 2005 ; 36: 178-186.
65. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007 ; 40: 108-115.
66. Kahn JA, Rosenthal SL, Hamann T., Bernstein DI Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS. 2003 ; 14: 300-306.
67. Olshen E., Woods ER, Austin SB, Luskin M., Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health. 2005 ; 37: 248-251.
68. Rosenthal SL, Rupp R., Zimet GD, et al. Uptake of HPV vaccine: demographics, sexual history and values, parenting style, and vaccine attitudes. J Adolesc Health. 2008 ; 43: 239-245.
69. Christini AB, Shutt KA, Byers KE Influenza vaccination rates and motivators among healthcare worker groups. Infect Control Hosp Epidemiol. 2007 ; 28: 171-177.
70. Shugarman LR, Hales C., Setodji CM, Bardenheier B., Lynn J. The influence of staff and resident immunization rates on influenza-like illness outbreaks in nursing homes. J Am Med Dir Assoc. 2006 ; 7: 562-567.
71. Daley MF, Liddon N., Crane LA, et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics. 2006 ; 118: 2280-2289.
72. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005 ; 37: 502-510.
73. Prislin R., Sawyer MH, Nader PR, Goerlitz M., De Guire M., Ho S. Provider-staff discrepancies in reported immunization knowledge and practices. Prev Med. 2002 ; 34: 554-561.
74. National Foundation for Infectious Diseases. Call to action: Adolescent vaccination-Bridging from a strong childhood foundation to a healthy adulthood. Bethesda, MD: National Foundation for Infectious Diseases ; 2005.
75. Centers for Disease Control and Prevention (CDC). Data 2010: the Healthy People 2010 database. Available at: http://wonder.cdc.gov/data2010/obj.htm. Accessed February 17, 2009.
76. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics. The National Immunization Survey (NIS). Available at: http://www.cdc.gov/nis/about-teen.htm. Accessed May 16, 2008.
77. Centers for Disease Control and Prevention (CDC). Vaccines for Children Program (VFC). Available at: http://www.cdc.gov/vaccines/programs/vfc/default. htm. Accessed August 14, 2008.
78. US Department of Health and Human Services. Children and adolescents vaccine financing table of recommendations adopted by NVAC-September 2008. Available at: http://www.hhs.gov/nvpo/nvac/CAVFRecommendationsSept08.html. Accessed January 28, 2009.
79. Centers for Medicare and Medicaid Services. State Children's Health Insurance Program (SCHIP). Available at: http://www.cms.hhs.gov/home/schip.asp. Accessed May 21, 2008.
80. National Vaccine Advisory Committee. Mandates for adolescent immunizations: recommendations from the National Vaccine Advisory Committee. Am J Prev Med. 2008 ; 35: 145-151.
81. National Vaccine Advisory Committee. Standards for child and adolescent immunization practices. Pediatrics. 2003 ; 112: 958-963.
82. Jacobson VJ, Szilagyi P. Patient reminder and patient recall systems to improve immunization rates. Cochrane Database Syst Rev. 2005 :CD003941.
83. CDC. Immunization Registry Progress-United States, January-December 2002. MMWR. 2004 ; 53: 431-433.
84. US Department of Health and Human Services. Enhancing participation in Immunization Information Systems (IIS): recommendations to the National Vaccine Advisory Committee. Available at: http://www.hhs.gov/nvpo/nvac/ IISRecommendationsSep08.html. Accessed January 28, 2009.
85. Centers for Disease Control and Prevention (CDC). Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation. A report of the National Vaccine Advisory Committee. MMWR Recomm Rep. 2000 ; 49 (RRO1). 1-13.
86. Planned Parenthood. HPV. Available at: http://www.plannedparenthood.org/ health-topics/stds-hiv-safer-sex/hpv-4272.htm#get. Accessed October 1, 2008.
87. Winnick S., Lucas DO, Hartman AL, Toll D. How do you improve compliance ? Pediatrics. 2005 ; 115: e718-724.
88. National Vaccine Advisory Committee. The promise and challenge of adolescent immunization. Am J Prev Med. 2008 ; 35: 152-157.
89. Rand CM, Shone LP, Albertin C., Auinger P., Klein JD, Szilagyi PG National health care visit patterns of adolescents: implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med. 2007 ; 161: 252-259.
90. Omer SB, Pan WK, Halsey NA, et al. Nonmedical exemptions to school immunization requirements: secular trends and association of state policies with pertussis incidence. JAMA. 2006 ; 296: 1757-1763.